The HATCH venture Complex Biotech Discovery Ventures (CBDV), a licensed cannabis and psilocybin research laboratory based at UBC, was acquired this month by Delic Corp. The company’s mission is to expand psychedelic wellness, including relevant psychedelic therapy like mushroom therapy and ketamine treatment, which can be used to treat pain and depression when correctly administered.
CBDV was co-founded in 2018 by UBC chemistry researchers Markus Roggen and Professor Glenn Sammis. The company specializes in high-precision chemical analytics and metabolomics identification, with an initial focus on cannabis. They were granted an exemption in January 2021 by Health Canada to develop new analytical methods for psilocybin mushrooms and study their metabolites. Acquiring CBDV will enable Delic to add intellectual property to its portfolio based on sound, peer-reviewed research in cannabis and psilocybin conducted by CBDV. This collaboration could lead to important new controlled biopharmaceuticals in the future.
HATCH is a startup accelerator located in ICICS and collaboratively managed by ICICS and entrepreneurship@UBC (e@UBC).